Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $134.32 USD
Change Today -2.21 / -1.62%
Volume 1.2M
BDX On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Snapshot

Open
$135.42
Previous Close
$136.53
Day High
$135.98
Day Low
$133.18
52 Week High
08/5/15 - $154.98
52 Week Low
09/22/14 - $112.15
Market Cap
28.2B
Average Volume 10 Days
1.5M
EPS TTM
$6.83
Shares Outstanding
210.3M
EX-Date
09/4/15
P/E TM
19.7x
Dividend
$2.40
Dividend Yield
1.79%
Current Stock Chart for BECTON DICKINSON AND CO (BDX)

becton dickinson and co (BDX) Related Businessweek News

View More BusinessWeek News

becton dickinson and co (BDX) Details

Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; and closed-system transfer devices. Its BD Life Sciences segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers. This segment’s products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood and tuberculosis culturing systems; molecular testing systems; microorganism identification and drug susceptibility systems; liquid-based cytology systems; rapid diagnostic assays; microbiology laboratory automation; and plated media. It also offers research and clinical tools, such as fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. In addition, the company develops technologies that address biological analysis protocols, including library preparation of next generation sequencing and genotyping applications. Becton, Dickinson and Company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

30,619 Employees
Last Reported Date: 11/26/14
Founded in 1897

becton dickinson and co (BDX) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $985.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $690.2K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $721.0K
Executive Vice President and President of Glo...
Total Annual Compensation: $605.7K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $900.8K
Compensation as of Fiscal Year 2014.

becton dickinson and co (BDX) Key Developments

Becton, Dickinson and Company Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015; Revises Earnings Guidance for the Year 2015

Becton, Dickinson and Company reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2015. For the quarter, the company reported revenues of $3,120 million against $2,157 million a year ago. Operating income was $137 million against $445 million a year ago. Income before income taxes was $39 million against $423 million a year ago. Net income was $62 million against $326 million a year ago. Diluted earnings per share was $0.29 against $1.65 a year ago. Adjusted revenues were $3.133 billion. Adjusted diluted earnings per share were $2.05, compared with $1.75 in the prior-year period. This represents an increase of 17.1% or 34.3% on a currency-neutral basis. For the nine months, the company reported revenues of $7,222 million against $6,244 million a year ago. Operating income was $779 million against $1,204 million a year ago. Income before income taxes was $549 million against $1,145 million a year ago. Net income was $514 million against $884 million a year ago. Diluted earnings per share was $2.52 against $4.47 a year ago. Adjusted diluted earnings per share were $5.22, compared with $4.77 in the prior-year period. This represents an increase of 9.4%, or 20.8% on a currency-neutral basis. Adjusted revenues were $7,235 million. The company expects currency-neutral adjusted revenues for the full fiscal year 2015, including the accretion from the acquisition of CareFusion, to grow 28.5 to 29.0%, which is at the high end of its previously communicated guidance range. Including the impact of foreign currency, adjusted revenues are expected to grow 21.0 to 21.5%, compared to 21.0 to 22.0% previously communicated due to an incrementally negative estimated impact from foreign currency. On a comparable, currency-neutral basis, the company continues to estimate organic revenue growth to be approximately 4.5%. As reported, the company expects full fiscal year revenues to grow 20.7 to 21.2%. On standalone basis, the company expects diluted earnings per share of $6.19 to $6.26 and adjusted fully diluted earnings per share of $6.40 to $6.147. Including CareFusion Accretion, the company expects diluted earnings per share of $3.85 to $5.99. The company is raising its full-year fiscal 2015 adjusted diluted earnings per share guidance to a range of $7.08 to $7.12. This represents growth of 20.0 to 21.0% on a currency-neutral basis. Including the incrementally negative estimated impact from foreign currency, the company expects adjusted diluted earnings per share growth of 8.5 to 9.5%.

Becton, Dickinson Keen On Acquisitions

Vince Folenza, Chairman, President and Chief Executive Officer said that the Becton, Dickinson and Company (NYSE:BDX) will continue to think about plug-in acquisitions and look forward to having more flexibility as debt levels down are lowered.

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2015

Becton, Dickinson and Company has declared a quarterly dividend of 60 cents per common share, payable on September 30, 2015 to holders of record on September 9, 2015. The indicated annual dividend rate is $2.40 per share.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $134.32 USD -2.21

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,666 JPY -34.50
Avago Technologies Ltd $121.15 USD -2.62
Boston Scientific Corp $16.24 USD -0.29
Mylan NV $48.05 USD +0.63
Stryker Corp $95.34 USD -1.34
View Industry Companies
 

Industry Analysis

BDX

Industry Average

Valuation BDX Industry Range
Price/Earnings 33.9x
Price/Sales 3.0x
Price/Book 4.0x
Price/Cash Flow 35.2x
TEV/Sales 1.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit www.bd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.